Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis.
Xi XieHaina GanJing TianFen LiJinwei ChenJia WangJiafeng LiaoShu Li
Published in: European journal of clinical investigation (2022)
Our preliminary data indicated T-614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF-β1/smad pathway in experimental SSc models and may be a promising therapeutic agent for SSc.